Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 31, 2015

View Archived Issues

Immune Pharmaceuticals enters exclusive license for novel bispecific antibody technology

University of Wisconsin generates vocal cord mucosae in vitro

HDAC inhibitor AR-42 prevents cancer cachexia in animal models

Initiation of phase III trial of CAM-2038 in opioid-dependent patients

Discovery Labs starts phase IIb trial of Aerosurf in premature infants with RDS

Minerva Neurosciences completes recruitment in phase IIb trial of MIN-101 in schizophrenia

FDA grants rare pediatric disease designation to RGX-111 for MPS I

TeaRx's oral anticoagulant Tearexaban completes phase II studies

Prexton Therapeutics plans first-in-human study of PXT-002331

Lixte licenses LB-100 rights in Asia to Taipei Medical University

Oryzon Genomics receives Spanish government funding for two projects

Six-panel biosignature shows promise as a point-of-care screening test for TB

Hutchison Medi Pharma plans phase I trial of HMPL-689

Epizyme starts trials of EZH2 inhibitor tazemetostat in INI1-negative tumors

CDK7 expression shows promise as a prognosis biomarker in TNBC

SNPs near CTNNA2 may be associated with impulsivity

NeuroDerm starts phase II trial comparing two dosing regimens of ND-0612H

Bristol-Myers Squibb patents MGAT2 inhibitors

GlaxoSmithKline describes STING modulators

Bristol-Myers Squibb reports development of NS5B inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...